Cargando…

Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic

Coronaviruses are pleomorphic, enveloped, or spherical viruses, which have a size ranging from 80 to 120 nm. These viruses act on receptors that cause the triggering of fusion. Coronaviruses were first described after cultivation from patients with common colds by Tyrell and Bynoe in 1966. There are...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhandari, Ranjana, Khanna, Garima, Kuhad, Anurag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550915/
https://www.ncbi.nlm.nih.gov/pubmed/33065092
http://dx.doi.org/10.1016/j.ejphar.2020.173643
_version_ 1783593067005083648
author Bhandari, Ranjana
Khanna, Garima
Kuhad, Anurag
author_facet Bhandari, Ranjana
Khanna, Garima
Kuhad, Anurag
author_sort Bhandari, Ranjana
collection PubMed
description Coronaviruses are pleomorphic, enveloped, or spherical viruses, which have a size ranging from 80 to 120 nm. These viruses act on receptors that cause the triggering of fusion. Coronaviruses were first described after cultivation from patients with common colds by Tyrell and Bynoe in 1966. There are various subtypes of coronavirus, 7 out of these can cause infection in human beings. The Alpha subtype is responsible for mild infection showing symptoms or infection without any prevailing symptoms. On the other hand, the beta subtype is responsible for very serious diseases leading to fatality. The lineage of this novel SARS-CoV-2 falls under the beta lineage of the beta coronavirus which has been observed to have a relation to the MERS and SARS coronavirus. In the Huanan market selling seafood, the transition of this novel virus in humans from animals has occurred. It has the potential to be the cause of widespread fatality amongst the people of the globe. On August 16, 2020, the World Health Organisation had reported 2,1294,845 cases which are confirmed to date out of which 413,372 deaths have occurred. Currently, no targeted antiviral vaccines or drugs to fight against COVID-19 infection have been approved for use in humans. This pandemic is fast emerging and drug repurposing is the only ray of hope which can ensure quick availability. Vaccine development is progressing each day with various platforms such as DNA, Live Attenuated Virus, Non-Replicating Viral Vector, Protein Subunit, and RNA, being utilized for the development. COVID-19 attacks the immune system of the host & this can result in a cytokine storm. As a result, various herbal agents both acting as antivirals and immunomodulatory can also be used. Convalescent Plasma Therapy and Mesenchymal Stem Cell therapy are also being explored as a plausible therapeutic. There remains a considerable unmet need for therapeutics to be addressed. The development and availability of accessible and efficient therapy are essential for the treatment of patients. This review discusses the epidemiology, pathogenesis, the tale of origin, and transmission of COVID-19 or Sars-Cov2 virus and gives evidence of potential therapeutic agents that can be explored to cast away this pandemic.
format Online
Article
Text
id pubmed-7550915
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75509152020-10-13 Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic Bhandari, Ranjana Khanna, Garima Kuhad, Anurag Eur J Pharmacol Full Length Article Coronaviruses are pleomorphic, enveloped, or spherical viruses, which have a size ranging from 80 to 120 nm. These viruses act on receptors that cause the triggering of fusion. Coronaviruses were first described after cultivation from patients with common colds by Tyrell and Bynoe in 1966. There are various subtypes of coronavirus, 7 out of these can cause infection in human beings. The Alpha subtype is responsible for mild infection showing symptoms or infection without any prevailing symptoms. On the other hand, the beta subtype is responsible for very serious diseases leading to fatality. The lineage of this novel SARS-CoV-2 falls under the beta lineage of the beta coronavirus which has been observed to have a relation to the MERS and SARS coronavirus. In the Huanan market selling seafood, the transition of this novel virus in humans from animals has occurred. It has the potential to be the cause of widespread fatality amongst the people of the globe. On August 16, 2020, the World Health Organisation had reported 2,1294,845 cases which are confirmed to date out of which 413,372 deaths have occurred. Currently, no targeted antiviral vaccines or drugs to fight against COVID-19 infection have been approved for use in humans. This pandemic is fast emerging and drug repurposing is the only ray of hope which can ensure quick availability. Vaccine development is progressing each day with various platforms such as DNA, Live Attenuated Virus, Non-Replicating Viral Vector, Protein Subunit, and RNA, being utilized for the development. COVID-19 attacks the immune system of the host & this can result in a cytokine storm. As a result, various herbal agents both acting as antivirals and immunomodulatory can also be used. Convalescent Plasma Therapy and Mesenchymal Stem Cell therapy are also being explored as a plausible therapeutic. There remains a considerable unmet need for therapeutics to be addressed. The development and availability of accessible and efficient therapy are essential for the treatment of patients. This review discusses the epidemiology, pathogenesis, the tale of origin, and transmission of COVID-19 or Sars-Cov2 virus and gives evidence of potential therapeutic agents that can be explored to cast away this pandemic. Elsevier B.V. 2021-01-05 2020-10-13 /pmc/articles/PMC7550915/ /pubmed/33065092 http://dx.doi.org/10.1016/j.ejphar.2020.173643 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Full Length Article
Bhandari, Ranjana
Khanna, Garima
Kuhad, Anurag
Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic
title Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic
title_full Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic
title_fullStr Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic
title_full_unstemmed Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic
title_short Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic
title_sort pharmacological insight into potential therapeutic agents for the deadly covid-19 pandemic
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550915/
https://www.ncbi.nlm.nih.gov/pubmed/33065092
http://dx.doi.org/10.1016/j.ejphar.2020.173643
work_keys_str_mv AT bhandariranjana pharmacologicalinsightintopotentialtherapeuticagentsforthedeadlycovid19pandemic
AT khannagarima pharmacologicalinsightintopotentialtherapeuticagentsforthedeadlycovid19pandemic
AT kuhadanurag pharmacologicalinsightintopotentialtherapeuticagentsforthedeadlycovid19pandemic